MedpaceMEDP
About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Employees: 5,900
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
14% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 81
12% more call options, than puts
Call options by funds: $26.1M | Put options by funds: $23.4M
4% more repeat investments, than reductions
Existing positions increased: 214 | Existing positions reduced: 206
0% more capital invested
Capital invested by funds: $8.38B [Q3] → $8.4B (+$26.7M) [Q4]
0.31% more ownership
Funds ownership: 81.06% [Q3] → 81.38% (+0.31%) [Q4]
0% more funds holding
Funds holding: 577 [Q3] → 578 (+1) [Q4]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities Jailendra Singh 34% 1-year accuracy 12 / 35 met price target | 1%upside $300 | Hold Maintained | 23 Apr 2025 |
Baird Eric Coldwell 43% 1-year accuracy 13 / 30 met price target | 5%upside $313 | Neutral Maintained | 23 Apr 2025 |
TD Cowen Charles Rhyee 13% 1-year accuracy 1 / 8 met price target | 10%upside $328 | Hold Downgraded | 14 Apr 2025 |
Mizuho Ann Hynes 52% 1-year accuracy 11 / 21 met price target | 19%upside $355 | Outperform Maintained | 9 Apr 2025 |
Leerink Partners Michael Cherny 70% 1-year accuracy 19 / 27 met price target | 11%upside $330 | Market Perform Initiated | 24 Mar 2025 |
Financial journalist opinion
Based on 11 articles about MEDP published over the past 30 days
